Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Burden of EGFR Exon 20 Mutation in NSCLC

April 25th 2018

Dr. Yu on Treatments for EGFR-Mutant Lung Cancer

April 23rd 2018

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.

Final Insight: PARPs and gBRCA in Breast Cancer

March 30th 2018

Testing for Germline BRCA Mutations in the Future

March 30th 2018

PARP Inhibitors in Other Subtypes of Breast Cancer

March 30th 2018

Distinguishing Between PARP Inhibitors in Breast Cancer

March 30th 2018

PARP Inhibitors and Platinum Sensitivity or Resistance

March 30th 2018

Additional PARPs Under Investigation for Breast Cancer

March 30th 2018

Using Olaparib in gBRCA1/2+ Breast Cancer

March 30th 2018

Olaparib: Predicting Response in Breast Cancer

March 30th 2018

Takeaways From the OlympiAD Trial

March 30th 2018

Chemotherapy in Early-Stage gBRCA1/2+ Breast Cancer

March 30th 2018

Chemotherapy in gBRCA1/2+ Metastatic Breast Cancer

March 30th 2018

Germline BRCA1/2: A New Subset of Breast Cancer

March 30th 2018

Implications for Germline BRCA Testing in Breast Cancer

March 30th 2018

Emerging Options for BRCA-Mutated Breast Cancer Treatment

March 30th 2018

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

March 19th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer

March 11th 2018

Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.

Dr. Robson on Exploratory Analysis From OlympiAD in Breast Cancer

March 9th 2018

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Dr. Gradishar on Using Genetic Testing to Identify Actionable Results in Breast Cancer

March 9th 2018

William J. Gradishar, MD, interim chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the utilization of genetic testing in breast cancer to identify actionable results for patients.